Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Istisociclib by Kronos Bio for Myxoid Liposarcoma: Likelihood of Approval
Istisociclib is under clinical development by Kronos Bio and currently in Phase II for Myxoid Liposarcoma. According to GlobalData, Phase...
Istisociclib by Kronos Bio for Uterine Cancer: Likelihood of Approval
Istisociclib is under clinical development by Kronos Bio and currently in Phase II for Uterine Cancer. According to GlobalData, Phase...
Istisociclib by Kronos Bio for Rectal Cancer: Likelihood of Approval
Istisociclib is under clinical development by Kronos Bio and currently in Phase II for Rectal Cancer. According to GlobalData, Phase...
Istisociclib by Kronos Bio for Germ Cell Tumors: Likelihood of Approval
Istisociclib is under clinical development by Kronos Bio and currently in Phase II for Germ Cell Tumors. According to GlobalData,...
Istisociclib by Kronos Bio for Bladder Cancer: Likelihood of Approval
Istisociclib is under clinical development by Kronos Bio and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...
Istisociclib by Kronos Bio for Colorectal Cancer: Likelihood of Approval
Istisociclib is under clinical development by Kronos Bio and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Kronos Bio's Istisociclib?
Istisociclib is a small molecule commercialized by Kronos Bio, with a leading Phase II program in Small-Cell Lung Cancer. According...